Table 3 Adverse events recorded in 4-h period after ingestion of investigational drugs (randomized patients dataset; n = 99)
Adverse event | PCF n (%) | NAP n (%) | PLA n (%) |
|---|---|---|---|
Nervousness | 11 (14.5) | 8 (12.1) | 12 (14.6) |
Palpitation | 4 (5.3) | 2 (3.0) | 3 (3.7) |
Insomnia | 4 (5.3) | 3 (4.6) | 3 (3.7) |
Dizziness | 6 (7.9) | – | 4 (4.9) |
Abdominal pain | 5 (6.6) | 4 (6.1) | 5 (6.1) |
Dyspepsia | 6 (7.9) | 7 (10.6) | 5 (6.1) |
Nausea | 15 (19.7) | 15 (22.7) | 21 (25.6) |
Vomiting | 2 (2.6) | 3 (4.6) | 2 (2.4) |
Drowsiness | 11 (14.5) | 14 (21.2) | 13 (15.9) |
Fatigue | 12 (15.8) | 10 (15.2) | 14 (17.1) |